The India-UK Free Trade Agreement (FTA) is poised to be a transformative force for India’s pharmaceutical and medical device sectors. With strategic tariff reductions and streamlined regulatory pathways, this landmark agreement is expected to fuel exceptional growth, facilitate exports, and enhance global collaborations for Indian companies.
Key Benefits of the India-UK FTA
1. Zero Tariff Commitment
The UK has agreed to zero tariffs on nearly 99% of Indian pharma exports. While the majority of Indian pharmaceutical exports to the UK were already duty-free, the FTA formalizes this arrangement, ensuring long-term clarity and stability for exporters. This stable environment empowers Indian companies to plan investments and market expansion with greater confidence.
2. Easing Market Access for Generics and Biosimilars
Indian firms specializing in generics and biosimilars stand to benefit significantly from the agreement. The UK’s robust demand for high-quality, affordable medicines aligns perfectly with what Indian companies offer, especially those known as a monopoly medicine company in India.
-
Product approvals are expected to be fast-tracked.
-
Indian brands can rapidly scale their presence in one of Europe’s most valuable healthcare markets.
3. Enhanced Supply Chains and Investment
According to industry experts, the agreement will:
-
Strengthen supply chains through reduced trade barriers and clearer regulations
-
Encourage foreign direct investment (FDI) in the pharma and medical device industries
-
Foster bulk drug imports and empower Indian firms acting as a pharma contract manufacturing company to form joint R&D ventures and CDMO (contract development and manufacturing organization) partnerships
4. Boosting Exports and Market Share
-
India’s pharmaceutical exports to the UK surpassed $910 million in FY24.
-
The UK pharma market stands at $45 billion and is projected to reach $73 billion by 2033.
-
The Indian share, notably in the generics segment, is already $5 billion and positioned for substantial growth due to the FTA.
5. Improving Access to Affordable Medicines
The reduced tariffs on generic medicines and key medical devices—such as surgical instruments and diagnostics—will:
-
Enhance affordability for UK consumers
-
Increase the appeal of Indian-made healthcare products in the UK
-
Help “monopoly medicine companies” and contract manufacturers supply more accessible, cost-effective solutions
Opportunities for Indian Pharma Companies
-
Regulatory streamlining will allow faster product launches and improved compliance.
-
Cross-border R&D and innovation will become easier through collaborations with UK entities.
-
The FTA opens doors for contract manufacturing and joint research, empowering Indian firms to stay competitive globally.
Expert Perspectives
Industry leaders highlight the FTA as a major milestone:
-
“The agreement strengthens supply chains, enhances access to affordable medicines, and drives FDI,” says Namit Joshi, Chairman, Pharmexcil.
-
Manoj Mishra from Grant Thornton Bharat notes that tariffs relief “boosts competitiveness of Indian generics and high-quality affordable healthcare solutions, positioning India to scale its footprint in one of Europe’s most valuable healthcare markets.”
Conclusion
The India-UK Free Trade Agreement signals a new era for Indian pharmaceutical and medical device exporters. By removing tariff barriers and facilitating regulatory cooperation, the FTA enables Indian companies—including monopoly medicine companies in India and pharma contract manufacturing companies—to broaden their access to UK drug stores, accelerate product approvals, invest in innovation, and deliver more affordable medicines to patients in the UK. This partnership not only enhances bilateral trade but also strengthens the foundations for global healthcare progress.